D18S880 Microsatellite Polymorphism of Carnosinase Gene and Diabetic Nephropathy: A Meta-Analysis

2013 ◽  
Vol 17 (4) ◽  
pp. 289-294 ◽  
Author(s):  
Ji-Min Zhu ◽  
Bin Wang ◽  
Jing Li ◽  
Gui-Mei Chen ◽  
Yin-Guang Fan ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Meta Analysis ◽  
Microsatellite Polymorphism ◽  
Carnosinase Gene

scholarly journals Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials

BMJ Open ◽  
2013 ◽  
Vol 3 (5) ◽  
pp. e002934 ◽  
Author(s):  
Uru Nezu ◽  
Hiroshi Kamiyama ◽  
Yoshinobu Kondo ◽  
Mio Sakuma ◽  
Takeshi Morimoto ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Kidney Function ◽  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Protein Diet ◽  
Low Protein Diet ◽  
Controlled Trials ◽  
Low Protein ◽  
Randomised Controlled

scholarly journals Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis

Diabetologia ◽  
2009 ◽  
Vol 52 (4) ◽  
pp. 691-697 ◽  
Author(s):  
G. M. Magee ◽  
R. W. Bilous ◽  
C. R. Cardwell ◽  
S. J. Hunter ◽  
F. Kee ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Meta Analysis ◽  
The Future ◽  
Future Risk

scholarly journals Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review

2015 ◽  
pp. 6275 ◽  
Author(s):  
Yu Zhang ◽  
Jing Xing ◽  
Xaojing Mu ◽  
Hui Wang ◽  
Lei Zhang ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Literature Review ◽  
Meta Analysis

scholarly journals Comparing the Efficacy of Angiotensin Converting Enzyme In-hibitors with Calcium Channel Blockers on the Treatment of Di-abetic Nephropathy: A Meta-Analysis

2019 ◽  
Author(s):  
Zhaowei ZHANG ◽  
Chunlin CHEN ◽  
Shiwen LV ◽  
Yalan ZHU ◽  
Tianzi FANG
Keyword(s):  
Blood Pressure ◽  
Diabetic Nephropathy ◽  
Angiotensin Converting Enzyme ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Mean Difference ◽  
Channel Blockers ◽  
Converting Enzyme

Background: The angiotensin-converting enzyme inhibitors (ACEIs) could improve the symptoms of diabetic nephropathy. Whether the calcium channel blockers (CCBs) could be as effective as ACEIs on treating diabetic nephropathy is controversial. Here, we aimed to compare the efficacy of ACEIs with CCBs on the treatment of diabetic nephropathy by performing a meta-analysis of randomized controlled trials (RCTs). Methods: The Pubmed, Medline, Embase and The Cochrane Database were searched up to July 2017 for eligible randomized clinical trials studies. Effect sizes were summarized as mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (P-value<0.05). Results: Seven RCTs involving 430 participants comparing ACEIs with CCBs were included. No benefit was seen in comparative group of ACEIs on systolic blood pressure（SBP） (MD=1.05 mmHg; 95% CI: -0.97 to 3.08, P=0.31), diastolic blood pressure (DBP) (MD= -0.34 mmHg; 95% CI: -1.2 to 0.51, P=0.43), urinary albumin excretion rates (UAER) (MD=1.91μg/min; 95% CI: -10.3 to 14.12, P=0.76), 24-h urine protein (24-UP) (SMD=-0.26; 95%CI: -0.55 to 0.03, P=0.08), glomerular filtration rate (GFR) (SMD=0.01; 95% CI: -0.38 to 0.41, P=0.95). On safety aspect, the risk of adverse reactions between ACEIs group and CCBs group are similar (RR=1.18; 95% CI: 0.61 to 2.28; P=0.61). Conclusion: Both ACEIs and CCBs could improve the BP, UAER, 24h-UP, and GFR of diabetic nephropathy to a similar extent

scholarly journals Effects of physical activity on the progression of diabetic nephropathy: a meta-analysis

2021 ◽  
Vol 41 (1) ◽  
Author(s):  
Zixin Cai ◽  
Yan Yang ◽  
Jingjing Zhang
Keyword(s):  
Physical Activity ◽  
Diabetic Nephropathy ◽  
Healthy Lifestyle ◽  
Meta Analysis ◽  
Kidney Injury ◽  
Cochrane Library ◽  
Diabetic Patients ◽  
Mean Differences

Abstract Background: Diabetic nephropathy (DN) is an important microvascular complication of diabetes. Physical activity (PA) is part of a healthy lifestyle for diabetic patients; however, the role of PA in DN has not been clarified. Our aim was to conduct a meta-analysis to explore the association between PA and DN risk. Methods: PubMed, Embase, Cochrane Library and Web of Science were systematically searched for articles examining PA in diabetic patients and its effect on renal function. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. The study protocol is registered with PROSPERO (CRD42020191379). Results: A total of 38991 participants were identified from 18 studies. The results indicated that PA was associated with increases in the glomerular filtration rate (SMD = 0.01, 95% CI = [0.02–0.17]) and decreases in the urinary albumin creatinine ratio (SMD = −0.53, 95% CI: −0.72 to −0.34), rate of microalbuminuria (OR = 0.61, 95% CI = [0.46–0.81]), rate of acute kidney injury (OR = 0.02, 95% CI = [0.01–0.04]), rate of renal failure (OR = 0.71, 95% CI = [0.52–0.97]) and risk of DN in patients with Type 1 diabetes (OR = 0.67, 95% CI = [0.51–0.89]). Conclusions: This meta-analysis indicated that PA is effective for improving DN and slowing its progression; however, more high-quality randomized controlled trials are required on this topic.

scholarly journals Perubahan Kadar Protein dalam Urin terhadap Penggunaan Obat Antihipertensi (Valsartan) pada Pasien Nefropati

2019 ◽  
Vol 4 (1) ◽  
pp. 1-6
Author(s):  
Selly Septi Fandinata
Keyword(s):  
Blood Pressure ◽  
Diabetic Nephropathy ◽  
Kidney Disease ◽  
Metabolic Disorder ◽  
Meta Analysis ◽  
Normal Blood ◽  
Normal Blood Pressure ◽  
Central Hospital ◽  
Inclusion Criteria ◽  
Chronic Complication

ABSTRAKDiabetes mellitus (DM) adalah suatu sindroma gangguan metabolisme yang dicirikan dengan hiperglikemia abnormal sebagai akibat dari suatu defisiensi sekresi insulin, berkurangnya efektivitas aktivitas biologis insulin atau adanya resistensi insulin. Komplikasi kronik mikrovaskular, salah satunya yaitu Penyakit Ginjal Diabetik. Penyakit Ginjal Diabetik didefinisikan secara klinik yaitu penyakit DM dengan proteinuria yang menetap dalam urin. Meta analisis melaporkan bahwa proteinuria merupakan marker terjadinya kerusakan ginjal. Beberapa penelitian membuktikan bahwa terapi ARB dapat menurunkan derajat proteinuria pada pasien ginjal-diabetik. Terapi ARB yang paling banyak digunakan di RSUD Dr. Sutomo adalah valsartan. Tujuan dari penelitian ini adalah untuk mengetahui perubahan kadar protein dalam urin terhadap penggunaan antihipertensi (valsartan) pada pasien penyakit Nefropati. Penelitian dilakukan di Instalasi Rawat Jalan Penyakit Dalam RSUD Dr. Sutomo. Kriteria Inklusi yaitu penderita penyakit ginjal diabetik di Instalasi rawat jalan dengan proteinuria dan tekanan darah terkontrol (≤130/80mmHg), yang menggunakan terapi antihipertensi tunggal valsartan. Kriteria Eksklusi yaitu hiperkalemia, ISK, menggunakan obat-obatan yang mempengaruhi proteinuria (NSAID, vit B6, B12) dan kontraindikasi terhadap valsartan. Dari penelitian ini disimpulkan bahwa pada pemberian valsartan tidak terjadi perubahan distribusi derajat proteinuria, dari 27 penderita 29,6% mengalami penurunan, 59,26% tetap dan 11,11% mengalami peningkatan derajat proteinuria. Kesimpulan pada penelitian ini bahwa valsartan tidak mengalami perubahan dalam menurunkan deraajat proteinuria.Kata kunci: nefropati, proteinuria, ARB, valsartan. ABSTRACTDiabetes Mellitus (DM) is a syndrome of metabolic disorder characterized by abnormal hyperglicemia. One of the chronic complication DM is renal microangiopathy called Diabetic Nephropathy (DN). In addition, clinical DN is defined as DM with proteinuria. Meta analysis reported proteinuria as a marker of kidney damage as predictor of progressive kidney disease is robust. Moreover several trials concluded ARBs treatment could reduce the level of proteinuria in DN patients. ARBs treatment used in RSUD Dr. Soetomo Central Hospital Surabaya is valsartan. The purpose of this study was to determine the effect of valsartan treatments on the proteinuria level in DN patients. This study was done at the outpatients clinic departement RSUD Dr. Soetomo Central Hospital Surabaya. The inclusion criteria were DN patients with normal blood pressure (≤130/80mmHg). Twenty seven patients were enrolled in this study. The result showed valsartan antiproteinuria, there was no change in proteinuria level distribution. From twenty seven patients 29,6% decreased, 59,26% did not change and 11,11% increased proteinuria level. As a conclusion, valsartan treatment no change in proteinuria level distribution.Keywords: diabetic nephropathy, proteinuria, ARBs, valsartan.

Sign in / Sign up

Export Citation Format

Share Document